ABSTRACT
75 patients with cancer were treated with Mitomycin-C, of which only 54 had evaluable results. Over-all response rate was 25/54 (48%) divided according to primary sites as colonic and small intestinal - 4/13 responses, breast - 5/9, liver - 3/4, gastric - 3/4, pancreatic - 2/4, gallbladder - 2/2, esophageal - 1/2, nasopharyngeal - 1/2, parotid - 1/1 and a case each of chondrosarcoma, rhabddomyosarcoma, mesothelioma, urinary bladder carcinoma, and reticulum cell sarcoma with no responsesMinor side-effects were anorexia (33%), nausea (33%), vomiting (20%), lassitude (20%) epilation (10%) and chills and fever (2.5% each). Major side-effects were leucopenia (11%) anemia (5.5%) and thrombocytopenia (4%). In the three of the patients with myelosuppression secondary to Mitomycin C, blood transfusions of 2 to 4 pints were administered because of moderate anemia. (Summary)